<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> occurs in various organs, most frequently in liver </plain></SENT>
<SENT sid="1" pm="."><plain>Serological examination including <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and biochemical markers for liver function evaluation is routinely performed, though its accuracy is not high </plain></SENT>
<SENT sid="2" pm="."><plain>MicroRNAs (miRNAs) have been implicated in a variety of human diseases including <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, and have many characteristics of an ideal biomarker most notably their inherent stability and resilience </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, several studies have indicated that circulating miRNAs hold much potential as novel noninvasive biomarkers for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and other disease processes </plain></SENT>
<SENT sid="4" pm="."><plain>The objective of this study was to investigate the potential of serum miRNAs as novel biomarkers for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: This study was divided into three phases: (I) 3 candidate serum miRNAs were detected by using real-time RT-PCR, corresponding 38 CRC patients with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> and 36 CRC patients without <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>(II) Marker validation by real-time RT-PCR on a similar cohort of age- and sex-matched <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients without (n=20) and with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> (n=20) </plain></SENT>
<SENT sid="7" pm="."><plain>(III) We examined the correlation between the expressions of candidate serum miRNAs with clinical parameters of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Serum miR-29a was significantly higher in colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> (CRLM) patients than in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="9" pm="."><plain>This marker yielded a receiver operating characteristic curve area of 80.3% </plain></SENT>
<SENT sid="10" pm="."><plain>At a cutoff value of 0.155, the sensitivity was 75% and the specificity was 75% in discriminating metastatic from non-metastatic patients </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, increased levels of miR-29a expression were also observed in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> from CRLM patients compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="12" pm="."><plain>No significant difference was observed in the levels of serum miR-92a between metastatic and non-metastatic patients </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: These findings suggest that serum miR-29a has strong potential as a novel noninvasive biomarker for early detection of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
</text></document>